{
  "id": 3170835,
  "title": "Anbogen Therapeutics partners with Tokyo University on ABT 301 research",
  "url": "https://urgent.news/2026/08/25/anbogen-therapeutics-partners-with-tokyo-university-on-abt-301",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-25T02:52:17.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/anbogen-therapeutics-partners-with-tokyo-university-on-abt-301-research-159284.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Anbogen Therapeutics has entered into a Collaborative Research Agreement with The University of Tokyo to evaluate its selective Class I histone deacetylase inhibitor, ABT-301 (Imofinostat), across multiple solid tumor types using veterinary oncology models. Led by experts from the Laboratory of Veterinary Surgery, this collaboration aims to generate scientific evidence to support the expansion of ABT-301's human clinical indications and optimize its combination strategies. The research team brings extensive expertise in translational oncology, cancer immunotherapy, and genomic medicine in companion animals, with a focus on naturally occurring cancers in dogs, which are widely recognized as clinically and molecularly analogous to their human counterparts.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}